Molecular insights into endocrine resistance

Johnston, 2003, Aromatase inhibitors for breast cancer: lessons from the laboratory, Nat Rev Cancer, 3, 821, 10.1038/nrc1211 Kumar, 1987, Functional domains of the human estrogen receptor, Cell, 51, 941, 10.1016/0092-8674(87)90581-2 Tzukerman, 1994, Human estrogen receptor transcriptional capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions, Mol Endocrinol, 8, 21, 10.1210/me.8.1.21 Kuiper, 1996, Cloning of a novel estrogen receptor expressed in rat prostate and ovary, 93, 5925 Cowley, 1999, A comparison of transcriptional activation by ER alpha and ER beta, J Steroid Biochem Mol Biol, 69, 165, 10.1016/S0960-0760(99)00055-2 Montano, 1995, The carboxy-terminal F domain of the human estrogen receptor; role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists, Mol Endocrinol, 9, 814, 10.1210/me.9.7.814 Spiers, 1999, Coexpression of estrogen receptor alpha and beta; poor prognostic factors in human breast cancer, Cancer Res, 59, 525 Webb, 1995, Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens, Mol Endocrinol, 9, 443, 10.1210/me.9.4.443 Paech, 1997, Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites, Science, 277, 1508, 10.1126/science.277.5331.1508 Schiff, 1997, Development of tamoxifen-stimulated growth in-vivo is associated with changes in AP-1 activity, Breast Cancer Res Treat, 46, A347 Johnston, 1999, Increased activator protein-1 DNA binding and c-jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance, Clin Cancer Res, 5, 251 Smith, 1997, Coactivator and co-repressor regulation of the agonist/antagonist activity of the mixed antiestrogen 4-hydroxytamoxifen, Mol Endocrinol, 11, 657, 10.1210/me.11.6.657 Lavinsky, 1998, Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes, 95(6), 2920 Kahlert, 2000, Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway, J Biol Chem, 275, 18447, 10.1074/jbc.M910345199 Simoncini, 2000, Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase, Nature, 407, 538, 10.1038/35035131 Levin, 2003, Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor, Mol Endocrinol, 17, 309, 10.1210/me.2002-0368 Shou, 2004, Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer, J Natl Cancer Inst, 96, 926, 10.1093/jnci/djh166 Osborne, 2005, Estrogen-receptor biology: continuing progress and therapeutic implications, J Clin Oncol, 23, 1616, 10.1200/JCO.2005.10.036 Mass, 2000, The role of HER-2 expression in predicting response to therapy in breast cancer, Semin Oncol, 27, 46 Ellis, 2001, Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial, J Clin Oncol, 19, 3808, 10.1200/JCO.2001.19.18.3808 Smith, 2003, Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial, Breast Cancer Res Treat, 82, S6 Osborne, 2003, Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer, J Natl Cancer Inst, 95, 353, 10.1093/jnci/95.5.353 Bardou, 2003, Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases, J Clin Oncol, 21, 1973, 10.1200/JCO.2003.09.099 Cui, 2003, Mol Endocrinol, 17, 575, 10.1210/me.2002-0318 Petz, 2004, Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site, Mol Endocrinol, 18, 521, 10.1210/me.2003-0105 Massarweh, 2004, Tamoxifen resistance in a breast cancer xenograft model coincides with a switch from an ER+/PgR+ to an ER+/PgR- phenotype accompanied by EGFR/HER2 activation, Breast Cancer Res Treat, 82, S18 Osborne, 2005, Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer, Clin Cancer Res, 11, 865s, 10.1158/1078-0432.865s.11.2 Thurlimann, 2005, BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer, 23, 6s Paik, 2004, A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer, N Engl J Med, 351, 2817, 10.1056/NEJMoa041588 Mouridsen, 1979, Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women, Cancer Treat Rep, 63, 171 Smith, 2003, Aromatase inhibitors in breast cancer, N Engl J Med, 348, 2431, 10.1056/NEJMra023246 Johnston, 1995, Changes in estrogen receptor, progesterone receptor and pS2 expression in tamoxifen-resistant human breast cancer, Cancer Res, 55, 3331 Gutierrez, 2005, Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase, J Clin Oncol, 23, 2469, 10.1200/JCO.2005.01.172 Parl, 2003, Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer, Pharmacogenomics J, 3, 251, 10.1038/sj.tpj.6500201 Yang, 2001, Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells, Cancer Res, 61, 7025 Wolf, 1994, The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain, Breast Cancer Res Treat, 31, 129, 10.1007/BF00689683 Karnik, 1994, Estrogen receptor mutations in tamoxifen-resistant breast cancer, Cancer Res, 54, 349 Andersen, 1997, Screening for ESR mutations in breast and ovarian cancer patients, Hum Mutat, 9, 531, 10.1002/(SICI)1098-1004(1997)9:6<531::AID-HUMU6>3.0.CO;2-4 Dowsett, 1997, Oestrogen receptor mutants and variants in breast cancer, Eur J Cancer, 33, 1177, 10.1016/S0959-8049(97)00100-7 Fuqua, 2000, A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions, Cancer Res, 60, 4026 Johnston, 1997, Acquired tamoxifen resistance in human breast cancer, potential mechanisms and clinical implications, Anticancer Drugs, 8, 911, 10.1097/00001813-199711000-00002 DeFriend, 1994, Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro, Br J Cancer, 70, 204, 10.1038/bjc.1994.281 Howell, 2002, Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment, J Clin Oncol, 20, 3396, 10.1200/JCO.2002.10.057 Osborne, 2002, Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial, J Clin Oncol, 20, 3386, 10.1200/JCO.2002.10.058 McClelland, 2001, Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex), Endocrinology, 142, 2776, 10.1210/en.142.7.2776 Knowlden, 2003, Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells, Endocrinology, 144, 1032, 10.1210/en.2002-220620 Stoica, 2003, Estradiol rapidly activates Akt via the ErbB2 signaling pathway, Mol Endocrinol, 17, 818, 10.1210/me.2002-0330 Font de Mora, 2000, AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor, Mol Cell Biol, 20, 5041, 10.1128/MCB.20.14.5041-5047.2000 Benz, 1993, Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu, Breast Cancer Res Treat, 24, 85, 10.1007/BF01961241 Kao, 1996, Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study, Cancer Res, 56, 3451 Sourdaine, 1994, Analysis of the aromatase cytochrome P450 gene in human breast cancers, J Mol Endocrinol, 13, 331, 10.1677/jme.0.0130331 Dowsett, 1992, Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients, J Steroid Biochem Mol Biol, 43, 155, 10.1016/0960-0760(92)90201-S Masamura, 1995, Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells, J Clin Endocrinol Metab, 80, 2918, 10.1210/jc.80.10.2918 Santen, 2001, Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients, J Steroid Biochem Mol Biol, 79, 115, 10.1016/S0960-0760(01)00151-0 Chan, 2002, Molecular changes associated with acquisition of estrogen hypersensitivity in MCF-7 breast cancer cells on long-term estrogen deprivation, J Steroid Biochem Mol Biol, 81, 333, 10.1016/S0960-0760(02)00074-2 Martin, 2003, Enhanced ER alpha, ERB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long-term estrogen deprivation, J Biol Chem, 278, 30458, 10.1074/jbc.M305226200 Song, 2004, The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane, 101, 2076 Song, 2002, Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells, Mol Cell Endocrinol, 193, 29, 10.1016/S0303-7207(02)00093-X Song, 2002, Linkage of rapid estrogen action to MAPK activation by ER alpha-Shc association and Shc pathway activation, Mol Endocrinol, 16, 116, 10.1210/me.16.1.116 Nicholson, 2004, Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer; new opportunities for therapy, Endocrine Relat Cancer, 11, 623, 10.1677/erc.1.00778 Yue, 2003, Adaptive hypersensitivity following long-term estrogen deprivation; involvement of multiple signal pathways, J Steroid Biochem Mol Biol, 86, 265, 10.1016/S0960-0760(03)00366-2 Jeng, 2000, Role of MAP kinase in the enhanced cell proliferation of long-term estrogen deprived human breast cancer cells, Breast Cancer Res Treat, 62, 167, 10.1023/A:1006406030612 Stephen, 2001, Insulin-like growth factor receptor levels are regulated by cell density and by long-term estrogen deprivation in MCF-7 human breast cancer cells, J Biol Chem, 276, 40080, 10.1074/jbc.M105892200 Nicholson, 1999, Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer, Endocrine Relat Cancer, 6, 373, 10.1677/erc.0.0060373 Jeng, 2000, Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells, Breast Cancer Res Treat, 62, 167, 10.1023/A:1006406030612 Nicholson, 2004, Nonendocrine Pathways and Endocrine Resistance Observations with Antiestrogens and Signal Transduction Inhibitors in Combination, Clin Cancer Res, 10, 346S, 10.1158/1078-0432.CCR-031206 Kurokawa, 2000, Inhibition of HER2/neu (erbB-2) and Mitogen-activated Protein Kinases Enhances Tamoxifen Action against HER2-overexpressing, Tamoxifen-resistant Breast Cancer Cells, Cancer Res, 60, 5887 Witters, 2002, Restoration of estrogen responsiveness by blocking the HER-2/neu pathway, Oncol Rep, 9, 1163 Yu, 2001, mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer, Endocrine Relat Cancer, 8, 249, 10.1677/erc.0.0080249 Gee, 2003, The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro, Endocrinology, 144, 5105, 10.1210/en.2003-0705 Massarweh, 2002, Inhibition of epidermal growth factor / HER2 receptor signaling using ZD1839 (Iressa) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors, 21, 33a Argiris, 2004, Synergistic interactions between tamoxifen and trastuzumab (Herceptin), Clin Cancer Res, 10, 1409, 10.1158/1078-0432.CCR-1060-02 Chu, 2005, The dual ErbB1/ErbB2 inhibitor lapatinib (GW572016) cooperates with tamoxifen to inhibit both cell proliferation and estrogen-dependent gene expression in antiestrogen resistant breast cancer, Cancer Res, 65, 18, 10.1158/0008-5472.18.65.1 End, 2001, Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro, Cancer Res, 61, 131 Kelland, 2001, Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer, Clin Cancer Res, 7, 3544 Johnston, 2002, Endocrine therapy combined with the farnesyltransferase inhibitor R115777 produces enhanced tumour growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in-vivo, Breast Cancer Res Treat, 76, A245 Ellis, 2003, Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines, Breast Cancer Res Treat, 78, 59, 10.1023/A:1022105511409 Long, 2004, Combining the farnesyl transferase inhibitor (FTI) lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer cells and tumor xenografts, 45, A3868 Doisneau-Sixou, 2003, Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression, Int J Cancer, 106, 789, 10.1002/ijc.11263 Rudolf, 2004, The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative FAD001 with the aromatase inhibitor letrozole in breast carcinomas, 45, A5619 DeGraffenried, 2004, Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity, Clin Cancer Res, 10, 8059, 10.1158/1078-0432.CCR-04-0035 Johnston, 2005, Combinations of endocrine and biological therapies; present status of therapeutic and pre-surgical studies, Clin Cancer Res, 11, 889s, 10.1158/1078-0432.889s.11.2